Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study

Ítems similars

• Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
  per: Ford, Janet H., et al.
  Publicat: (2020)
• A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
  per: Camporeale, Angelo, et al.
  Publicat: (2018)
• Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
  per: Ford, Janet H., et al.
  Publicat: (2019)
• Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
  per: Bangs, Mark E., et al.
  Publicat: (2020)
• Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
  per: Ford, Janet H, et al.
  Publicat: (2018)